Showing results (91-100 of 119) with videos related to

Sort By:
Pageof 12
Reumatologia Clinica|May 10, 2023
Gender biases in Spanish rheumatology: Perception and factsConcepción Delgado Beltrán, Isabel Castrejón, Blanca Hernández-Cruz, et al.
The Journal of Rheumatology|June 2, 2024
Long-Term Survival of Subcutaneous Biosimilar Tumor Necrosis Factor Inhibitors Compared to Originators: Results From a Multicenter Prospective RegistryMaría Paz Martínez-Vidal, Cristina Fernández-Carballido, Lucía Otero-Varela, et al.
Annals of the Rheumatic Diseases|August 16, 2020
Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort studyJose L Pablos, María Galindo, Loreto Carmona, et al.
Case Reports in Immunology|February 25, 2021
Erratum to "Partial and Transient Clinical Response to Omalizumab in IL-21-Induced Low STAT3-Phosphorylation on Hyper-IgE Syndrome"Cesar Daniel Alonso-Bello, María Del Carmen Jiménez-Martínez, María Eugenia Vargas-Camaño, et al.
Case Reports in Immunology|July 30, 2019
Partial and Transient Clinical Response to Omalizumab in IL-21-Induced Low STAT3-Phosphorylation on Hyper-IgE SyndromeCesar Daniel Alonso-Bello, María Del Carmen Jiménez-Martínez, María Eugenia Vargas-Camaño, et al.
Annals of the Rheumatic Diseases|April 9, 2024
Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registryBlanca Hernández-Cruz, Lucía Otero-Varela, Mercedes Freire-González, et al.
Arthritis Care & Research|October 24, 2022
Female Sex, Age, and Unfavorable Response to Tumor Necrosis Factor Inhibitors in Patients With Axial Spondyloarthritis: Results of Statistical and Artificial Intelligence-Based Data Analyses of a National Multicenter Prospective RegistryCristina Fernández-Carballido, Carlos Sanchez-Piedra, Raquel Valls, et al.
European Journal of Clinical Investigation|September 16, 2023
Real-world persistence of initial targeted therapy strategy in monotherapy versus combination therapy in patients with chronic inflammatory arthritisLorena Exposito, Carlos Sánchez-Piedra, Paloma Vela-Casasempere, et al.
Annals of the Rheumatic Diseases|June 14, 2020
Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseasesJose L Pablos, Lydia Abasolo, Jose M Alvaro-Gracia, et al.
Arthritis Research & Therapy|February 23, 2024
Impact of multimorbidity on the first ts/bDMARD effectiveness and retention rate after two years of follow-up in patients with rheumatoid arthritis from the BIOBADASER registryJerusalem Calvo-Gutiérrez, Clementina López-Medina, Lucía Otero-Varela, et al.
Pageof 12